PRMT5 Inhibitor Synergizes with Chemotherapy to Induce Resembling Mismatch Repair Deficiency and Enhance Anti‐TIGIT Therapy in Microsatellite‐Stable Colorectal Cancer

PRMT5 Inhibitor Synergizes with Chemotherapy to Induce Resembling Mismatch Repair Deficiency and Enhance Anti‐TIGIT Therapy in Microsatellite‐Stable Colorectal Cancer

Abstract Microsatellite stable (MSS) colorectal cancer (CRC) is considered an “immune‐cold” tumor, accounting for ≈85% of all CRC cases. The overall response rate to chemotherapy combined with immune checkpoint inhibitors in MSS CRC is typically less than 10%. The specific mechanism that enhances ch...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiang Zhu, Shenao Fu, Xi Zou, Hanjiang Zeng, Guangzu Cui, Yinghui Peng, Diya Tang, Fan Zhang, Hong Shen, Shan Zeng, Ying Han
Format: Article
Language:English
Published: Wiley 2025-07-01
Series:Advanced Science
Subjects:
anti‐tumor immunity
cGAS–STING signaling
colorectal cancer
epigenetic therapies
PRMT5
Online Access:https://doi.org/10.1002/advs.202500271
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items